A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
Purpose: Fedratinib, an oral, selective Janus kinase 2 inhibitor with activity against both wild-type and mutant Janus kinase 2, has pH-dependent solubility, with free solubility at pH 1. Concomitant administration of drugs that reduce gastric acid secretion, such as pantoprazole, may decrease the a...
| Published in: | Cancer Chemotherapy & Pharmacology Vol. 85; no. 5; pp. 995 - 1002 |
|---|---|
| Main Authors: | , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Springer Nature
May2020
|
| Online Access: | View this record in EBSCOhost |